EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1

Niklas Beschorner, Paul Künzle, Maike Voges, Ilona Hauber, Daniela Indenbirken, Jacqueline Nakel, Sanamjeet Virdi, Peter Bradtke, Niels Christian Lory, Michael Rothe, Maciej Paszkowski-Rogacz, Frank Buchholz und 7 weitere

PLOS ONE · 08.03.2024 · 19 (3) · e0298542

DOI: 10.1371/journal.pone.0298542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 08.03.2024. Verfasst von Niklas Beschorner und 18 weiteren Autor:innen. Beteiligte Einrichtung: Leibniz-Institute of Virology (LIV), Hamburg, Germany. Hauptthemen laut MEDLINE: HIV-1, HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Else Kröner-Fresenius-Stiftung, Free and Hanseatic City of Hamburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-based antiretroviral therapies (ART) efficiently suppress HIV replication in humans, but the virus persists as integrated proviral reservoirs in small numbers of cells. Importantly, ART cannot eliminate HIV from an infected individual, since it does not target the integrated provirus. Therefore, genome editing-based strategies that can inactivate or excise HIV genomes would provide the technology for novel curative therapies. In fact, the HIV-1 LTR-specific designer-recombinase Brec1 has been shown to remove integrated proviruses from infected cells and is highly efficacious on clinical HIV-1 isolates in vitro and in vivo , suggesting that Brec1 has the potential for clinical development of advanced HIV-1 eradication strategies in people living with HIV. In line with the preparation of a first-in-human advanced therapy medicinal product gene therapy trial, we here present an extensive preclinical evaluation of Brec1 and lentiviral vectors expressing the Brec1 transgene. This included detailed functional analysis of potential genomic off-target sites, assessing vector safety by investigating vector copy number (VCN) and the risk for potential vector-related insertional mutagenesis, as well as analyzing the potential of Brec1 to trigger an undesired strong T cell immune response. In conclusion, the antiviral designer-recombinase Brec1 is shown to lack any detectable cytopathic, genotoxic or T cell-related immunogenic effects, thereby meeting an important precondition for clinical application of the therapeutic lentiviral vector LV-Brec1 in novel HIV-1 curative strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHumansLentivirusRecombinasesProvirusesHIV Long Terminal RepeatGenetic Vectors

Substanzen

Recombinases

Autor:innen und Institutionen

  • Leibniz-Institute of Virology (LIV), Hamburg, Germany.
  • German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany.
  • PROVIREX Genome Editing Therapies GmbH, Hamburg, Germany.
  • Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
  • Medical Systems Biology, UCC, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.

ORCID-Profile: Jan Chemnitz

Förderung

  • Bundesministerium für Bildung und Forschung
  • Else Kröner-Fresenius-Stiftung
  • Free and Hanseatic City of Hamburg
  • H.W. & J. Hector Stiftung
  • European Union Horizon 2020 program

Zitieren

APA

Beschorner, N., Künzle, P., Voges, M., Hauber, I., Indenbirken, D., Nakel, J., Virdi, S., Bradtke, P., Lory, N. C., Rothe, M., Paszkowski-Rogacz, M., Buchholz, F., Grundhoff, A., Schambach, A., Thirion, C., Mittrücker, H. W., Schulze Zur Wiesch, J., Hauber, J., & Chemnitz, J. (2024). Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1. PLOS ONE, 19(3), e0298542. https://doi.org/10.1371/journal.pone.0298542

Vancouver

Beschorner N, Künzle P, Voges M, Hauber I, Indenbirken D, Nakel J, et al. Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1. PLOS ONE. 2024;19(3):e0298542. doi:10.1371/journal.pone.0298542

BibTeX
@article{Beschorner2024,
  author = {Beschorner, Niklas and Künzle, Paul and Voges, Maike and Hauber, Ilona and Indenbirken, Daniela and Nakel, Jacqueline and Virdi, Sanamjeet and Bradtke, Peter and Lory, Niels Christian and Rothe, Michael and Paszkowski-Rogacz, Maciej and Buchholz, Frank and Grundhoff, Adam and Schambach, Axel and Thirion, Christian and Mittrücker, Hans-Willi and Schulze Zur Wiesch, Julian and Hauber, Joachim and Chemnitz, Jan},
  title = {Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {3},
  pages = {e0298542},
  doi = {10.1371/journal.pone.0298542}
}
Kostenlos starten →